SG11201407318UA - Compositions and methods for the treatment of metabolic syndrome - Google Patents

Compositions and methods for the treatment of metabolic syndrome

Info

Publication number
SG11201407318UA
SG11201407318UA SG11201407318UA SG11201407318UA SG11201407318UA SG 11201407318U A SG11201407318U A SG 11201407318UA SG 11201407318U A SG11201407318U A SG 11201407318UA SG 11201407318U A SG11201407318U A SG 11201407318UA SG 11201407318U A SG11201407318U A SG 11201407318UA
Authority
SG
Singapore
Prior art keywords
international
formula
compositions
de
metabolic syndrome
Prior art date
Application number
SG11201407318UA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN1853CH2012 priority Critical
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Priority to PCT/IB2013/051596 priority patent/WO2013168016A1/en
Publication of SG11201407318UA publication Critical patent/SG11201407318UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in position 1,2, e.g. lipoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/168016 A1 (51) International Patent Classification: C07F 9/09 (2006.01) A61P 3/00 (2006.01) C07C 309/63 (2006.01) A61P3/10 (2006.01) A61K31/683 (2006.01) (21) International Application Number: PCT/IB2013/051596 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 28 February 2013 (28.02.2013) English English (30) Priority Data: 1853/CHE/2012 10 May 2012 (10.05.2012) IN (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) V© i-H o 00 i-H en i-H o CJ o & (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME (57) Abstract: The invention discloses the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II), and the methods of treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injec - tion. The compositions may be used treat to fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glue - ose tolerance, insulin resistance, high blood pressure, central obesity, overweight with fat deposits mainly around the waist, de­ creased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver progressing to NAFLD, polycystic ovarian syndrome, hy­ pophosphatemia, renal diseases, albuminuria, end stage renal disease and acanthosis nigricans.
SG11201407318UA 2012-05-10 2013-02-28 Compositions and methods for the treatment of metabolic syndrome SG11201407318UA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1853CH2012 2012-05-10
PCT/IB2013/051596 WO2013168016A1 (en) 2012-05-10 2013-02-28 Compositions and methods for the treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
SG11201407318UA true SG11201407318UA (en) 2014-12-30

Family

ID=54193692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407318UA SG11201407318UA (en) 2012-05-10 2013-02-28 Compositions and methods for the treatment of metabolic syndrome

Country Status (4)

Country Link
US (1) US9403857B2 (en)
SG (1) SG11201407318UA (en)
WO (1) WO2013168016A1 (en)
ZA (1) ZA201408053B (en)

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US2807644A (en) 1954-08-20 1957-09-24 Parke Davis & Co Pantethine inhibitors
FR3447M (en) 1963-08-20 Merck Ag E Derivatives of lipoic acid.
US4011342A (en) 1971-06-02 1977-03-08 Seperic Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
US4404366A (en) 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
JPS6318584B2 (en) 1979-11-29 1988-04-19 Nippon Chemiphar Co
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (en) 1982-03-10 1988-02-24 Ausonia Farma Srl Compound to attivita 'analgesic, antiinflammatory and mucoregulating process for its preparation and related pharmaceutical compositions
FR2528038B2 (en) 1982-06-04 1985-08-09 Lafon Labor Derivatives of benzhydrylsulphinylacetamide and their use in therapeutic
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5104887A (en) 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (en) 1983-10-20 1985-05-20 Toyo Pharma- Kk Morphinan derivative, production thereof and antitumor agent containing said compound
IL73293A (en) 1983-11-04 1988-02-29 Abbott Lab Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (en) 1984-02-02 1989-12-14 Yason Srl antibroncopneumopatico Agent.
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
JPH0380127B2 (en) 1985-06-04 1991-12-24 Suntory Ltd
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
DE69016335T2 (en) 1989-10-06 1995-06-01 Fujirebio Kk Pantothenic acid derivatives.
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (en) 1990-06-06 1995-01-26 Yason Srl Agent antitussive and mucoregolatore, its preparation and pharmaceutical compositions
FR2699077B1 (en) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions associated with trauma.
FR2707637B1 (en) 1993-06-30 1995-10-06 Lafon Labor Novel acetamide derivatives, process for their preparation and their use in therapy.
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
SE9401727D0 (en) 1994-05-18 1994-05-18 Astra Ab In New Compounds
FR2722199B3 (en) 1994-07-11 1996-09-06 Univ Picardie Jules Verne Etab Derivatives of valproic acid and their applications as medicines
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
PL334516A1 (en) 1996-11-22 2000-02-28 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl)amino cid amides, pharmaceutic agent containing them and method of inhibiting eduction and/or synthesis of beta-amyloid peptide using such compounds
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
PL200666B1 (en) 1998-02-27 2009-01-30 Sankyo Company, Limited Cyclic amine compounds
JP3761324B2 (en) 1998-05-15 2006-03-29 ヤンマー農機株式会社 Passenger rice transplanter
CA2385990A1 (en) 1999-09-29 2001-04-05 The Procter & Gamble Company Compositions having improved stability
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
EP1165487A1 (en) 1999-04-06 2002-01-02 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
WO2002009769A2 (en) 2000-07-27 2002-02-07 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
DE60130014T2 (en) 2000-10-24 2008-05-08 Ajinomoto Co., Inc. Method for producing the b-form of nateglinide crystals
DE10103506A1 (en) 2001-01-26 2002-08-14 Ingo S Neu A pharmaceutical composition for the treatment of Multiple Sclerosis
KR20060028821A (en) 2001-05-02 2006-04-03 유로-셀티크 소시에떼 아노뉨 Once-a-day oxycodone formulations
CN101675926A (en) 2001-08-29 2010-03-24 恩德制药公司 Analgesics and methods of use
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
JP4615866B2 (en) 2002-04-15 2011-01-19 ノバルティス アーゲー Crystal form of N- (trans-4-isopropylcyclohexylcarbonyl) -D-phenylalanine
NZ535692A (en) 2002-04-16 2006-07-28 Astellas Pharma Inc Medicament for preventing and/or treating chronic rejection
US7060725B2 (en) 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
AU2003303196B2 (en) 2002-12-19 2010-03-25 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
RU2317817C2 (en) 2003-02-14 2008-02-27 Пьер Фабр Медикаман Using milnacipran (1s,2r)-enantiomer for preparing drug
US7157589B2 (en) 2003-03-04 2007-01-02 Ortho-Mcneil Pharmaceutical, Inc. One step process for the preparation of anticonvulsant derivatives
AU2004289174B2 (en) 2003-07-29 2011-05-19 Signature R&D Holdings, Lcc Amino acid prodrugs
ES2368916T3 (en) 2003-10-14 2011-11-23 Xenoport, Inc. Crystal form of an analog of gamma-aminobutírico acid.
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
WO2005051913A1 (en) 2003-11-28 2005-06-09 Sankyo Company, Limited Cyclic amine derivative having heteroaryl ring
DE10361259A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss
CN1248690C (en) 2004-03-25 2006-04-05 华中师范大学 Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease
EA200601648A1 (en) 2004-04-07 2007-04-27 Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Glucosamine and general procedures glucosamine / anti-inflammatory agent, compositions and methods
CA2563489C (en) 2004-04-29 2013-06-18 Caldwell Galer, Inc. Topical methadone compositions and methods for using the same
CN1672678A (en) 2004-05-03 2005-09-28 深圳微芯生物科技有限责任公司 Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn
US7342131B2 (en) 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
CN100455560C (en) 2004-06-09 2009-01-28 中国人民解放军军事医学科学院放射医学研究所 Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use
AU2006225005A1 (en) 2005-03-18 2006-09-21 Ripped Formulations Ltd. Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
US20080221111A1 (en) 2005-05-11 2008-09-11 Nycomed Gmbh Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative
DE102005022276A1 (en) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivatives of dihydroxyphenylalanine
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
TW200720252A (en) 2005-05-27 2007-06-01 Sankyo Co Cyclic amine derivative having substituted alkyl group
EP1940398A1 (en) 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
JPWO2007086493A1 (en) 2006-01-27 2009-06-25 旭化成ファーマ株式会社 Nasal medication
US20070259930A1 (en) 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP2101766B1 (en) 2006-12-14 2016-09-21 Knopp Biosciences LLC Compositions and methods of using (r)-pramipexole
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CN100573950C (en) 2006-12-14 2009-12-23 财团法人工业技术研究院;力晶半导体股份有限公司;南亚科技股份有限公司;茂德科技股份有限公司;华邦电子股份有限公司 Phase-change storage apparatus and method of manufacture
US20100316712A1 (en) 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008089008A2 (en) 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin prodrugs
ES2319024B1 (en) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedure for obtaining entacapona substantially free of isomero z, its synthesis intermediates and new crystal form.
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
EP2152709B1 (en) 2007-05-01 2012-02-22 Concert Pharmaceuticals Inc. Morphinan compounds
EP1997493A1 (en) 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
WO2009002297A1 (en) 2007-06-22 2008-12-31 Gluconova Llc Halide-free glucosamine-acidic drug complexes
US20090075942A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fosamprenavir
CN101390854A (en) 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 Medical composition containing riluzole
WO2009056791A1 (en) 2007-11-02 2009-05-07 Pliva Hrvatska D.O.O. Processes for preparing pharmaceutical compounds
US20090118365A1 (en) 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CN101186583B (en) 2007-12-20 2011-05-11 吉林大学 Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
WO2009148698A1 (en) * 2008-06-02 2009-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of nsaids
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
CN101569618B (en) 2008-04-30 2011-11-09 上海医药工业研究院 Application of long-chain fatty acid derivative or plant extracts containing same in inhibiting the activity of aromatizing enzyme
KR100990949B1 (en) 2008-06-09 2010-10-29 엔자이텍 주식회사 Method for Preparing Clopidogrel and Derivatives Thereof
BRPI0915536A2 (en) 2008-07-08 2019-01-15 Catabasis Pharmaceuticals Inc acetylated fatty acid salicylates and their uses
WO2010022177A2 (en) 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
AU2009283813B2 (en) 2008-08-22 2015-02-19 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
WO2010073124A2 (en) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (en) 2009-04-06 2011-01-04 Ems Sa phthalimide derivatives of nonsteroidal antiinflammatory compounds and / or modulators of tnf- (alpha), process for obtaining them, pharmaceutical compositions containing them and their uses in the treatment of inflammatory diseases
NZ734905A (en) 2009-04-29 2019-05-31 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
EA201290007A1 (en) 2009-08-10 2013-01-30 Беллус Хелс Инк. Methods, connections and compositions for delivery 1,3-propandide sulphates
CN102002053A (en) 2009-09-02 2011-04-06 陕西合成药业有限公司 Tetrahydro thienopyridine derivative for treating
CN101717392A (en) 2009-10-09 2010-06-02 苏州凯达生物医药技术有限公司 Method for preparing rotigotine and derivative thereof
CN102050815B (en) 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug
CN101724934B (en) 2009-11-10 2012-07-04 东华大学 Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof
ES2364011B1 (en) 2009-11-20 2013-01-24 Gp Pharm, S.A. Capsules of pharmaceutical active and esters of polyinsaturated fatty acids for the treatment of cardiovascular diseases.
EP2521447B1 (en) 2010-01-08 2017-06-14 Catabasis Pharmaceuticals, Inc. Fatty acid fumarate derivatives and their uses
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma AS Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
RU2436772C2 (en) 2010-01-28 2011-12-20 Закрытое акционерное общество "НПК ЭХО" 4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20130190327A1 (en) 2010-02-26 2013-07-25 Catabasis Pharmaceuticals Inc Bis-fatty acid conjugates and their uses
AU2011263423B2 (en) 2010-06-08 2016-10-20 Krisani Biosciences (P) Ltd Cysteamine derivatives and their use in the treatment of NASH
DK2593094T3 (en) 2010-07-12 2018-03-12 Sanofi Aventis Deutschland Authentic composition containing bromhexin
WO2012025213A2 (en) 2010-08-23 2012-03-01 Grünenthal GmbH Novel therapeutic compounds
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (en) 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof
ES2655084T3 (en) 2010-10-29 2018-02-16 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2013008182A1 (en) 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
CN102336767A (en) 2011-07-11 2012-02-01 华东理工大学 Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative
WO2013017974A1 (en) 2011-07-30 2013-02-07 Mahesh Kandula Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013168022A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en) 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease
CN102633799B (en) 2012-04-10 2014-06-25 凯莱英医药集团(天津)股份有限公司 Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route
WO2013167988A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of cough
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
CN104603090A (en) 2012-05-10 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for the treatment of metabolic syndrome

Also Published As

Publication number Publication date
US20150080345A1 (en) 2015-03-19
WO2013168016A1 (en) 2013-11-14
ZA201408053B (en) 2016-04-28
US9403857B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
KR101763674B1 (en) Nuclear receptor binding agents
TW201105677A (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO1995003308A1 (en) Morphinan derivative and medicinal use
CN105541814A (en) Process for the preparation of compounds useful as inhibitors of SGLT
BRPI0507734A (en) compound or a salt, prodrug or solvate thereof, method of treating glk-mediated diseases, and process for the preparation of a compound
EP1334973A1 (en) Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts
ES2317052T3 (en) Useful therapeutic agents for the treatment of pain.
MX2007009661A (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses.
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201408800VA (en) Manufacture of 2- (5- bromo-4-(4-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid
WO2008049027A1 (en) Talarazole metabolites
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
KR20060037399A (en) Piperidine compounds and pharmaceutical compositions containing them
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
MX351656B (en) Novel antagonists of the glucagon receptor.
BRPI0509298A (en) compound, pharmaceutical composition, methods of inhibiting histamine h3 receptor in a mammal, to treat or prevent a nervous system disorder, obesity, and a disorder or disease, and, use of a compound
JP4272261B2 (en) 3-pyridyl enantiomers and their use as analgesics
TW200916440A (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PT1556354E (en) Therapeutic piperazine derivates useful for treating pain
TW201032804A (en) 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
SG11201408064PA (en) Macrocyclic inhibitors of flaviviridae viruses
BRPI0510365A (en) compound, method of producing a compound, nk2 receptor antagonist, prodrug, pharmaceutical agent, methods for antagonizing an nk2 receptor and preventing or treating functional gastrointestinal disorders, and use of the compound or a prodrug thereof
SG11201408501UA (en) Preparation, uses and solid forms of obeticholic acid
CZ2002204A3 (en) Medicament for treating inhibition of transport, extraction, or absorption of phosphate and pharmaceutical preparation
SG11201403402VA (en) Compounds